Two-Drug combo shows promise for tough pancreatic cancer
NCT ID NCT05068752
First seen Apr 02, 2026 · Last updated Apr 24, 2026 · Updated 3 times
Summary
This study tested whether combining two oral chemotherapy drugs, vemurafenib and sorafenib, could help control advanced pancreatic cancer with a KRAS mutation. Ten patients whose cancer had worsened after at least two prior treatments took the drug combination. The main goal was to see how many patients had their cancer stop growing or shrink after 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
Conditions
Explore the condition pages connected to this study.